^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-08046044

    i
    Other names: PF-08046044, SGN-35C, PF08046044, SGN35C, PF 08046044, SGN 35C
    Company:
    Pfizer
    Drug class:
    Topoisomerase I inhibitor, CD30-targeted antibody-drug conjugate
    Related drugs:
    10d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=58, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns
    Trial termination
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    18d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Completed --> Active, not recruiting
    Enrollment closed
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    22d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Completed, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Completed
    Trial completion
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    25d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Apr 2029 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    7ms
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=210 --> 46
    Enrollment closed • Enrollment change
    |
    PF-08046044
    1year
    SGN35C-001: A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Recruiting, Seagen Inc. | Trial completion date: Aug 2028 --> Apr 2029
    Trial completion date
    |
    PF-08046044
    2years
    SGN35C-001: A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PF-08046044
    over2years
    A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Not yet recruiting, Seagen Inc.
    New P1 trial
    |
    PF-08046044